Cargando…
Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune respons...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/ https://www.ncbi.nlm.nih.gov/pubmed/35335014 http://dx.doi.org/10.3390/vaccines10030382 |
_version_ | 1784676070397575168 |
---|---|
author | Papadokostaki, Eleni Tentolouris, Anastasios Anastasiou, Ioanna A. Psichogiou, Mina Iliaki, Evangelia Eleftheriadou, Ioanna Hatzakis, Angelos Tentolouris, Nikolaos |
author_facet | Papadokostaki, Eleni Tentolouris, Anastasios Anastasiou, Ioanna A. Psichogiou, Mina Iliaki, Evangelia Eleftheriadou, Ioanna Hatzakis, Angelos Tentolouris, Nikolaos |
author_sort | Papadokostaki, Eleni |
collection | PubMed |
description | The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune response in participants with and without DM after vaccination with the BNT162b2 mRNA vaccine. A total of 174 participants (58 with and 116 without diabetes, matched for age) were included. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, and 70–75 days after the second and before the third dose of the vaccine. Antibodies were measured by an anti-SARS-CoV-2 receptor-binding domain IgG (Abs-RBD-IgG) assay by a chemiluminescent microparticle immune assay; values > 50 AU/mL are considered protective from severe disease. Almost 17% of participants with DM did not develop adequate humoral immune response to the BNT162b2 mRNA vaccine after the first dose; however, it was high and similar after the second dose in both participants with and without DM and remained so almost 2 months after the second dose of the vaccine. Geometric mean values of Abs-RBD-IgG were not significantly different between participants with and without DM during the study. At least two doses of the BNT162b2 vaccine are necessary to ensure adequate and sustainable immune response in people with DM. |
format | Online Article Text |
id | pubmed-8954340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89543402022-03-26 Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study Papadokostaki, Eleni Tentolouris, Anastasios Anastasiou, Ioanna A. Psichogiou, Mina Iliaki, Evangelia Eleftheriadou, Ioanna Hatzakis, Angelos Tentolouris, Nikolaos Vaccines (Basel) Brief Report The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2. However, data regarding immune response in people with diabetes mellitus (DM) after vaccination with the BNT162b2 vaccine are limited. In this prospective observational study, we examined humoral immune response in participants with and without DM after vaccination with the BNT162b2 mRNA vaccine. A total of 174 participants (58 with and 116 without diabetes, matched for age) were included. Antibodies were measured 21 days after the first dose, 7–15 days after the second dose, and 70–75 days after the second and before the third dose of the vaccine. Antibodies were measured by an anti-SARS-CoV-2 receptor-binding domain IgG (Abs-RBD-IgG) assay by a chemiluminescent microparticle immune assay; values > 50 AU/mL are considered protective from severe disease. Almost 17% of participants with DM did not develop adequate humoral immune response to the BNT162b2 mRNA vaccine after the first dose; however, it was high and similar after the second dose in both participants with and without DM and remained so almost 2 months after the second dose of the vaccine. Geometric mean values of Abs-RBD-IgG were not significantly different between participants with and without DM during the study. At least two doses of the BNT162b2 vaccine are necessary to ensure adequate and sustainable immune response in people with DM. MDPI 2022-03-02 /pmc/articles/PMC8954340/ /pubmed/35335014 http://dx.doi.org/10.3390/vaccines10030382 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Papadokostaki, Eleni Tentolouris, Anastasios Anastasiou, Ioanna A. Psichogiou, Mina Iliaki, Evangelia Eleftheriadou, Ioanna Hatzakis, Angelos Tentolouris, Nikolaos Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
title | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
title_full | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
title_fullStr | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
title_full_unstemmed | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
title_short | Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study |
title_sort | immunogenicity of sars-cov-2 bnt162b2 vaccine in people with diabetes: a prospective observational study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954340/ https://www.ncbi.nlm.nih.gov/pubmed/35335014 http://dx.doi.org/10.3390/vaccines10030382 |
work_keys_str_mv | AT papadokostakieleni immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT tentolourisanastasios immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT anastasiouioannaa immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT psichogioumina immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT iliakievangelia immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT eleftheriadouioanna immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT hatzakisangelos immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy AT tentolourisnikolaos immunogenicityofsarscov2bnt162b2vaccineinpeoplewithdiabetesaprospectiveobservationalstudy |